Martin MacKay, EVP & Global Head of R&D at ALEXION PHARMACEUTICALS INC (ALXN), sold 3,340 shares at $131.70 ($439K) on 2017-02-28, disclosed to the SEC on 2017-03-01.
Seasonal sale ($439k) by EVP & Global Head of R&D — this insider has traded ALXN in February in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $131.20 | 860 | $113K | 25.7% |
| 2 | $131.20 | 860 | $113K | 25.7% |
| 3 | $131.70 | 625 | $82K | 18.7% |
| 4 | $131.70 | 625 | $82K | 18.7% |
| 5 | $132.50 | 370 | $49K | 11.2% |
| Total | $131.53 avg | 3,340 |
| $439K |
| 100% |
| Filing → |
| ALXN | SELL | 2017-02-08 | $684K | — | Filing → |
| ALXN | SELL | 2016-05-18 | $1.1M | — | Filing → |
| ALXN | SELL | 2016-03-01 | $139K | — | Filing → |